Correction | GenomeWeb



In last week’s Pharmacogenomics Reporter, the story “Roche Looks to Take Lead in Emerging 'Theranostics' Space With p53 AmpliChip,” erroneously reported that Roche is already using the p53 chip to stratify patients during clinical trials of Nutlin. In fact, the company is using the test to stratify patients in trials of other drugs in the company’s pipeline. The company still plans on forming partnerships with other pharma companies interested in the p53 chip.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.